Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
5-ALA versus MAL photodynamic therapy for superficial basal cell carcinoma
NL-OMON50578Phase 3Recruiting
- Sponsor
- Maastricht University Medical Center+
- Start
- Aug 2013
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in basal cell carcinoma (BCC) comparing Fractionated 5-ALA 20% PDT with MAL PDT in 2 sessions (2 arms). Primary endpoint: Treatment failure at 5 years. Started Aug 2013; status: recruiting.
02
Drugs
5-aminolevulinic acidmethyl aminolevulinate
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on NL-OMON50578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50578.